Clinical characteristics of COVID-19 patients with asthma in Wuhan, China: a retrospective cohort study

Jin, Meng; Chen, Can; Huang, Jinyu; Zhang, Fengqin; Dong, Tianyi; Zhang, Ming; Yue, Huihui; Liu, Kui; Li, Guangcai; Hu, Ke; Zhang, Huilan

doi:10.1080/02770903.2020.1850768

Cited by 12 publications

(9 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Early reports from March 2020 suggested that asthma patients were more likely to have severe COVID-19 requiring intensive care unit (ICU) admission. 5 , 6 Data from the large UK database OPENSafely with data collected from March 2020 to May 2020 showed that those with asthma or COPD taking inhaled corticosteroids (ICS) or oral corticosteroids had higher COVID-19–related mortality than the overall population, but this may have been affected by confounding of the indication for ICS. 7–9 Other large database studies that included patients between February and April 2020 or from March to August 2020, respectively, from the UK or USA, showed that while COPD was a risk factor for mortality in univariate analysis, asthma was not associated with increased death.…”

Section: Introductionmentioning

confidence: 99%

Epidemiology, Healthcare Resource Utilization, and Mortality of Asthma and COPD in COVID-19: A Systematic Literature Review and Meta-Analyses

Halpin¹,

Rabe²,

Loke³

et al. 2022

JAA

View full text Add to dashboard Cite

Purpose There has been concern that asthma and chronic obstructive pulmonary disease [COPD] increase the risk of developing and exacerbating COVID-19. The effect of medications such as inhaled corticosteroids (ICS) and biologics on COVID-19 is unclear. This systematic literature review analyzed the published evidence on epidemiology and the burden of illness of asthma and COPD, and the use of baseline medicines among COVID-19 populations. Patients and Methods Using Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, Embase®, MEDLINE® and Cochrane were searched (January 2019–August 2021). The prevalence of asthma or COPD among COVID-19 populations was compared to the country-specific populations. Odds ratios (ORs) were estimated to compare healthcare resource utilization (HCRU) rates, and meta-analyses of outcomes were estimated from age-adjusted ORs (aORs) or hazard ratios (aHRs). Meta-analyses of COVID-19 outcomes were conducted using random effects models for binary outcomes. Results Given the number and heterogeneity of studies, only 183 high-quality studies were analyzed, which reported hospitalization, intensive care unit (ICU) admissions, ventilation/intubation, or mortality. Asthma patients were not at increased risk for COVID-19–related hospitalization (OR = 1.05, 95% CI: 0.92 to 1.20), ICU admission (OR = 1.21, 95% CI: 0.99 to 1.1.48), ventilation/intubation (OR = 1.24, 95% CI: 0.95 to 1.62), or mortality (OR = 0.85, 95% CI: 0.75 to 0.96). Accounting for confounding variables, COPD patients were at higher risk of hospitalization (aOR = 1.45, 95% CI: 1.30 to 1.61), ICU admission (aOR = 1.28, 95% CI: 1.08 to 1.51), and mortality (aOR = 1.41, 95% CI: 1.37 to 1.65). Sixty-five studies reported outcomes associated with ICS or biologic use. There was limited evidence that ICS or biologics significantly impacted the risk of SARS-CoV-2 infection, HCRU, or mortality in asthma or COPD patients. Conclusion In high-quality studies included, patients with asthma were not at significantly higher odds for adverse COVID-19–related outcomes, while patients with COPD were at higher odds. There was no clear evidence that baseline medication affected outcomes. Registration PROSPERO (CRD42021233963).

show abstract

Section: Introductionmentioning

confidence: 99%

Epidemiology, Healthcare Resource Utilization, and Mortality of Asthma and COPD in COVID-19: A Systematic Literature Review and Meta-Analyses

Halpin¹,

Rabe²,

Loke³

et al. 2022

JAA

View full text Add to dashboard Cite

show abstract

“…It was observed in a study in China, including 21 asthmatics and 100 non‐asthmatic COVID‐19 adult patients who were compared after matching for age, sex, and comorbidity, that the intensive care unit admission rate for COVID‐19 was higher in the asthmatic group 21 . In a study conducted with adult COVID‐19 patients in the United States, the rate of asthma was found to be 14.4% and it was found that being asthmatic or using inhaled steroids, inhaled steroids/long‐acting beta‐agonists, or systemic steroids at the time of diagnosis of COVID‐19 was not associated with the risk of hospitalization 22 .…”

Section: Discussionmentioning

confidence: 99%

Attitudes towards influenza and pneumococcal vaccines in parents of asthmatic children during the COVID‐19 pandemic

Özer

Başkaya

Bostancı

2022

Pediatric Pulmonology

View full text Add to dashboard Cite

Objective: This study aimed to determine the differences in attitudes and views towards influenza and pneumococcal vaccines in parents of children with asthma during the COVID-19 pandemic.Materials and Methods: Asthmatic children in the 6-18 age group who were admitted to the pediatric allergy clinic of our hospital between October 1, 2020 and February 31, 2021 were included in the study. The parents were given a questionnaire asking about their demographics and medical history. Their attitudes and thoughts towards these two vaccines, both before and during the pandemic, and their COVID-19 stories were questioned.Results: A total of 78 patients diagnosed with asthma were included in this study.While the rate of influenza vaccination before the pandemic was 29.5%, the rate of those who received or wanted to receive influenza vaccine during the pandemic was 71.8% (p = 0.001). It was observed that the rate of influenza vaccination during the pandemic increased with the regular use of asthma medication, the presence of atopy, and a history of COVID-19 infection in the family/close environment. In total, 69.2% of the parents stated that their child's pneumococcal vaccination was incomplete or they were unaware of their child's vaccination status. Conclusion:This study demonstrated that there was an increase in the rate and willingness of parents of asthmatic children to have their children vaccinated against influenza during the COVID-19 pandemic. As for the pneumococcal vaccine, the majority of the parents did not have enough information or they were unaware of the vaccination status of their children. K E Y W O R D S allergy, asthma and early wheeze, COVID-19, influenza vaccine, pneumococcal vaccine 1 | INTRODUCTION After the World Health Organization (WHO) reported cases of pneumonia of unknown etiology in Wuhan, China, on December 31, 2019, it was understood that the causative agent of the disease was a new type of virus from the Coronavirus family detected for the first time in humans on January 7, 2020 and was named severe acute respiratory syndrome 2 on January 19, 2020. The disease was abbreviated as COVID-19 and was declared a global pandemic by the WHO in March 2020. 1 Studies have shown that mortality and morbidity in COVID-19are associated with certain chronic diseases. 2 Diseases such as cardiovascular diseases, obesity, diabetes, chronic lung diseases, hypertension and cancer in adults, and diabetes, adrenal insufficiency, chronic lung diseases, cancer, immunodeficiencies, and chronic kidney failure in children increase the mortality and morbidity related to COVID-19. 3,4 Regarding asthma, the most common chronic disease of childhood,

show abstract

“…A total of 114 eligible studies 2 , 3 , 4 , 5 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 ,…”

Section: Tableunclassified

Prevalence of comorbid tuberculosis amongst COVID‐19 patients: A rapid review and meta‐analysis

Wang

et al. 2021

Int J Clin Pract

View full text Add to dashboard Cite

Tuberculosis is reported to be associated with the severity and mortality amongst patients with coronavirus disease 2019 (COVID-19). 1 However, the reported prevalence of comorbid tuberculosis amongst COVID-19 patients varied greatly across the published studies. For example, the low prevalence of comorbid tuberculosis amongst COVID-19 patients was reported in Tian et al's study (0.4%) 2 and Yan et al's study (0.2%) 3 and the relatively high prevalence of comorbid tuberculosis amongst COVID-19 patients was reported in Hu et al's study (4.5%) 4 and Zhang et al's study (9.0%). 5 Therefore, it is needed to quantitatively estimate the pooled prevalence of comorbid tuberculosis amongst COVID-19 patients using a meta-analysis.

show abstract

Clinical characteristics of COVID-19 patients with asthma in Wuhan, China: a retrospective cohort study

Cited by 12 publications

References 33 publications

Epidemiology, Healthcare Resource Utilization, and Mortality of Asthma and COPD in COVID-19: A Systematic Literature Review and Meta-Analyses

Epidemiology, Healthcare Resource Utilization, and Mortality of Asthma and COPD in COVID-19: A Systematic Literature Review and Meta-Analyses

Attitudes towards influenza and pneumococcal vaccines in parents of asthmatic children during the COVID‐19 pandemic

Prevalence of comorbid tuberculosis amongst COVID‐19 patients: A rapid review and meta‐analysis

Contact Info

Product

Resources

About